🚀 VC round data is live in beta, check it out!
Polaryx Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Polaryx Therapeutics and similar public comparables like Corbus Pharmaceuticals, Sangamo Therapeutics, Vaxcell-Bio, Prestige Biologics and more.
Polaryx Therapeutics Overview
About Polaryx Therapeutics
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small molecule drug candidates designed to address core pathological mechanisms common to LSDs.
Founded
2014
HQ
Employees
11
Website
Sectors
Financials (FY)
EV
$147M
Polaryx Therapeutics Financials
Polaryx Therapeutics reported last fiscal year revenue of — and negative EBITDA of ($8M).
In the same fiscal year, Polaryx Therapeutics generated ($8M) in EBITDA losses and had net loss of ($9M).
Polaryx Therapeutics P&L
In the most recent fiscal year, Polaryx Therapeutics reported revenue of — and EBITDA of ($8M).
Polaryx Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($8M) | XXX | XXX | XXX |
| Net Profit | ($8M) | XXX | ($9M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Polaryx Therapeutics Stock Performance
Polaryx Therapeutics has current market cap of $147M, and enterprise value of $147M.
Market Cap Evolution
Polaryx Therapeutics' stock price is $3.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $147M | $147M | — | XXX | XXX | XXX | $-0.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPolaryx Therapeutics Valuation Multiples
Polaryx Therapeutics trades at (18.8x) EV/EBITDA.
Polaryx Therapeutics Financial Valuation Multiples
As of March 28, 2026, Polaryx Therapeutics has market cap of $147M and EV of $147M.
Equity research analysts estimate Polaryx Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Polaryx Therapeutics has a P/E ratio of (18.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $147M | XXX | $147M | XXX | XXX | XXX |
| EV (current) | $147M | XXX | $147M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (18.8x) | XXX | XXX | XXX |
| EV/EBIT | (19.5x) | XXX | (18.8x) | XXX | XXX | XXX |
| P/E | (18.4x) | XXX | (17.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (37.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Polaryx Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Polaryx Therapeutics Margins & Growth Rates
Polaryx Therapeutics' revenue in the last fiscal year grew by —.
Polaryx Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 80% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Polaryx Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Corbus Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Sangamo Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Vaxcell-Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Prestige Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mersana Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Polaryx Therapeutics M&A Activity
Polaryx Therapeutics acquired XXX companies to date.
Last acquisition by Polaryx Therapeutics was on XXXXXXXX, XXXXX. Polaryx Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Polaryx Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPolaryx Therapeutics Investment Activity
Polaryx Therapeutics invested in XXX companies to date.
Polaryx Therapeutics made its latest investment on XXXXXXXX, XXXXX. Polaryx Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Polaryx Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Polaryx Therapeutics
| When was Polaryx Therapeutics founded? | Polaryx Therapeutics was founded in 2014. |
| Where is Polaryx Therapeutics headquartered? | Polaryx Therapeutics is headquartered in United States. |
| How many employees does Polaryx Therapeutics have? | As of today, Polaryx Therapeutics has over 11 employees. |
| Is Polaryx Therapeutics publicly listed? | Yes, Polaryx Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Polaryx Therapeutics? | Polaryx Therapeutics trades under PLYX ticker. |
| When did Polaryx Therapeutics go public? | Polaryx Therapeutics went public in 2026. |
| Who are competitors of Polaryx Therapeutics? | Polaryx Therapeutics main competitors are Corbus Pharmaceuticals, Sangamo Therapeutics, Vaxcell-Bio, Prestige Biologics. |
| What is the current market cap of Polaryx Therapeutics? | Polaryx Therapeutics' current market cap is $147M. |
| Is Polaryx Therapeutics profitable? | No, Polaryx Therapeutics is not profitable. |
| What is the current net income of Polaryx Therapeutics? | Polaryx Therapeutics' last 12 months net income is ($8M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.